{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:06:52Z","timestamp":1783462012979,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.coph.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T14:10:13Z","timestamp":1619100613000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Current status of hepatitis delta"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6591","authenticated-orcid":false,"given":"Margarita","family":"Papatheodoridi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-4060","authenticated-orcid":false,"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cld.2019.04.005","article-title":"HBV\/HDV coinfection: a challenge for therapeutics","volume":"23","author":"Koh","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.coph.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_sref3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2020.06.037","article-title":"The burden of hepatitis D \u2013 defogging the epidemiological horizon","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_sref4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14357","article-title":"New epidemiology of hepatitis delta","volume":"40","author":"Vlachogiannakos","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.coph.2021.03.008_bib7","first-page":"3","article-title":"A\u00a0review on hepatitis D: from virology to new therapies","volume":"17","author":"Mentha","year":"2019","journal-title":"J\u00a0Adv Res"},{"key":"10.1016\/j.coph.2021.03.008_bib8","series-title":"Global hepatitis report","year":"2017"},{"key":"10.1016\/j.coph.2021.03.008_sref9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.03.008_sref10","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.03.008_sref11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jhep.2020.05.019","article-title":"Revisiting the estimation of hepatitis D global prevalence","volume":"73","author":"Miao","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/gutjnl-2018-317874","article-title":"Hepatitis D prevalence: problems with extrapolation to global population estimates","volume":"69","author":"Stockdale","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.03.008_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2018-317403","article-title":"Devil hepatitis D: an orphan disease or largely underdiagnosed?","volume":"68","author":"Wedemeyer","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.03.008_bib15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/gutjnl-2019-318691","article-title":"Hepatitis D: not a rare disease anymore: global update for 2017\u20132018","volume":"69","author":"Shen","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.03.008_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/cid\/ciz001","article-title":"Prevalence of hepatitis B and hepatitis D virus infections in the\u00a0United States, 2011\u20132016","volume":"69","author":"Patel","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2021.03.008_bib18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.03.008_bib20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/hep.28957","article-title":"A\u00a0novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_bib21","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/infdis\/jiy157","article-title":"Hepatitis D viremia among injection drug users in San Francisco","volume":"217","author":"Mahale","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.03.008_sref22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2018.09.058","article-title":"Pathogenesis of and new therapies for hepatitis D","volume":"156","author":"Koh","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.03.008_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/JCM.02027-16","article-title":"Performance characteristics of\u00a0a new consensus commercial kit for hepatitis D virus RNA\u00a0viral load quantification","volume":"55","author":"Le Gal","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.coph.2021.03.008_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/liv.14729","article-title":"The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal","volume":"41","author":"Rizzetto","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.coph.2021.03.008_bib25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jvh.13081","article-title":"New treatment options for delta virus: is a cure in sight?","volume":"25","author":"Yurdaydin","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.coph.2021.03.008_bib26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_bib27","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.03.008_bib28","first-page":"CD006002","article-title":"Interferon alpha for chronic hepatitis D","author":"Abbas","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.03.008_bib29","article-title":"New Insights into hepatitis D virus persistence: the role of interferon response and implications for upcoming novel therapies","author":"Zhang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib30","doi-asserted-by":"crossref","first-page":"104995","DOI":"10.1016\/j.antiviral.2020.104995","article-title":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis","volume":"185","author":"Abdrakhman","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.coph.2021.03.008_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.03.008_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate\u00a0for hepatitis D (HIDIT-II): a randomised, placebo\u00a0controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.03.008_bib33","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2021.03.008_bib34","first-page":"496A","article-title":"A\u00a0phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV Study","volume":"66","author":"Hamid","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_bib35","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0168-8278(20)30774-1","article-title":"A\u00a0phase 2 study of peginterferon lambda, lonafarnib, and ritonavir for 24 Weeks: end-of-study results from the LIFT HDV study","volume":"73","author":"Koh","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.03.008_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib39","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV coinfection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib40","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A\u00a0prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.coph.2021.03.008_bib41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2021.03.008_bib42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.03.008_bib43","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(17)30310-0","article-title":"A\u00a0phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.03.008_bib45","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/S0168-8278(18)31266-2","article-title":"Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV co-infection: 18-month follow-up results from the REP 301-LTF study","volume":"68","author":"Bazinet","year":"2018","journal-title":"J\u00a0Hepatol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:52:47Z","timestamp":1761461567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":45,"alternative-id":["S1471489221000291"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.03.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of hepatitis delta","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}